[{"orgOrder":0,"company":"Sera Labs","sponsor":"CURE Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Sera Labs","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Topical Cream","sponsorNew":"Sera Labs \/ CURE Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Sera Labs \/ CURE Pharmaceutical"}]

Find Clinical Drug Pipeline Developments & Deals by Sera Labs

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Acquisition of Sera Labs will add to CURE a growing brand portfolio and monetization platform that fits remarkably well with CURE’s development capabilities, products, and existing market verticals.

                          Brand Name : Seratopical

                          Molecule Type : Small molecule

                          Upfront Cash : $20.0 million

                          July 28, 2020

                          Lead Product(s) : Cannabidiol,Aspartame

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Sponsor : CURE Pharmaceutical

                          Deal Size : $44.0 million

                          Deal Type : Acquisition

                          blank